Latest Conference Articles

The use of 2 separate recommended phase 2 doses of Talquetamab was associated with high response rates in patients with heavily pre-treated relapsed/refractory multiple myeloma.

Comparing intensive remission induction chemotherapy prior to allogeneic hematopoietic cell transplantation to watchful waiting followed by sequential conditioning did not show superior results.

Salvage chemotherapy after lintuzumab-Ac225 showed promising early efficacy results in patients with relapsed/refractory acute myeloid leukemia by eliminating residual leukemia cells.

Joseph M. Scandura, MD, PhD, provides an overview on the research of pelabresib which will be discussed at the 2022 American Society of Hematology Annual Meeting.

Pretreatment with Obinutuzumab aids fixed-duration regimen of glofitamab in high complete responses among a group of heavily pretreated patients with relapsed or refractory mantle cell lymphoma.

In the phase 1b/2 DESTINY-Breast07 study, positive results were shown with trastuzumab deruxtecan, even without the addition of pertuzumab.

Survival advantage was shown in a phase 3 study of neoadjuvant chemotherapy/carboplatin in patient with triple negative breast cancer.

Improvement in progression-free and overall survival was shown with sacituzumab govitecan in the phase 3 TROPiCS-02 trial.

Longer follow-up in the phase 3 STIC CTC trial substantiates that the CTC-based choice is safe in patients with metastatic breast cancer, according to investigators.

Patients with ER-positive/HER2-negative metastatic breast cancer demonstrated improvement in progression-free survival when administered elacestrant vs standard of endocrine therapy.

Treatment with various camizestrant monotherapy doses lead to survival benefit compared with fulvestrant in a post-menopausal patient population diagnosed with estrogen receptor–positive, HER2-negative advanced breast cancer.

The combination of palbociclib and fulvestrant beyond progression on prior CDK4/6 inhibitor did not show significant improvements in progression-free survival compared with fulvestrant alone in ER-positive/HER2-negative breast cancer.

Maryam Lustberg, MD, MPH, explains how the HER2 low session during the 2022 San Antonio Breast Cancer Symposium.

Results from the VERITAC trial presented at the 2022 San Antonio Breast Cancer Symposium showed that ARV-471 monotherapy may be active in ER-positive/HER2-negative locally advanced/metastatic breast cancer.

Findings from the phase 3 CAPItello-291 trial show that the combination of capivasertib plus fulvestrant achieved improvement in progression-free survival among patients with hormone-receptor–positive/HER2-negative advanced breast cancer.

Findings from the HER2CLIMB clinical trial of tucatinib combined with trastuzumab and capecitabine verified the safety of the regimen in patients with HER2-positive metastatic breast cancer.

The use of trastuzumab deruxtecan in the neoadjuvant setting showed promising responses in patients with early-stage breast cancer.

Patients with advanced HER2-positive breast cancer had better progression-free and overall survival outcomes when given trastuzumab deruxtecan versus capecitabin-based treatment.

Trastuzumab deruxtecan demonstrated a clinically meaningful and statistically significant improvement in overall versus TDM-1 as well as a continued PFS benefit, according to Sara A. Hurvitz, MD.

According to Ruth O'Regan, MD, BCI is the first genomic assay to demonstrate benefit from ovarian suppression.

Among premenopausal patients, the addition of everolimus to endocrine therapy improved iDFS and OS, which is hypothesis generating, said Mariana Chavez-MacGregor, MD.

The data from 2 years post primary efficacy analysis of monarchE study showed that adjuvant abemaciclib plus endocrine therapy improves invasive disease-free survival.

Residual disease after neoadjuvant chemotherapy tumor microenvironment of metastasis doorway density is higher in Black women, potentially explaining poorer outcomes.

Pre- and postmenopausal patient with breast cancer may experience cognitive impairment with chemotherapy and endocrine therapy, according to RxPONDER PRO substudy results presented during SABCS 2022.

Yielding a 46% reduction in the risk of disease progression of death compared with combination chemotherapy, ribociclib plus endocrine therapy may be a new standard of care for patients with pre/perimenopausal HR-positive, HER2-negative advanced breast cancer

During a presentation, Emmanuel S. Antonarakis, MD explained that homologous repair mutations and mismatch mutations in prostate cancer have therapeutic implications in the context of PARP inhibitors and PD-1 inhibitors.

According to Alicia Morgans, MD, MPH, there is a consistent differentiation and benefit when AR-targeted agent is added to the androgen deprivation therapy plus docetaxel backbone.

Joshua J. Meeks, MD, discusses investigational targets in the bladder cancer space.

In an interview with Targeted Oncology, Ashley Ross, MD, PhD, discussed his recent advanced in prostate cancer, research around prostate cancer genomics, PET for staging and for identification of local disease, and more.

Results presented at the 2022 International Kidney Cancer Symposium show tivozanib continues to demonstrate progression-free survival benefit over sorafenib in relapsed or refractory renal cell carcinoma.